Sun Pharma Withdraws 11 Eye Care Products: Silence on Cause Raises Questions
Linus tackles things head-on. He takes sides in his analysis and it fits excellently with our editorial policy. No 'maybe's' and 'allegedly' for him, only things in black and white.
View all posts by this Author
By Linus Garg
First publised on 2026-08-03 03:44:53
About the Author
Linus tackles things head-on. He takes sides in his analysis and it fits excellently with our editorial policy. No 'maybe's' and 'allegedly' for him, only things in black and white.
View all posts by this Author
India's largest pharmaceutical company, Sun Pharmaceutical Industries Ltd., has voluntarily withdrawn 11 ophthalmic products from the Indian market, directing distributors and retailers to stop sales and return existing stocks. The products withdrawn are Depopred 2 ml, Brinolar (BKC Free), Brinzotim Eye Drops 5 ml (BKC Free), Lotepred 5 ml, Lotepred 1% Eye Drops 5 ml, Lotepred LS 0.2% Eye Drops 5 ml, Lotepred T, Nepalact OD Eye Drops 3 ml, Nepalact-Z, Toba-F and Nepalact Eye Drops 5 ml.
The withdrawal was initiated through a communication to distributors dated July 17, although it came to wider public attention only after media reports in recent days.
These are not niche products. They are routinely prescribed for glaucoma, post-operative inflammation, allergic eye disease and bacterial eye infections, conditions where interruption of treatment can carry significant clinical consequences.
Sun Pharma has described the action only as a precautionary measure, with a company spokesperson stating that patient safety remains its highest priority and that teams are working to restore the availability of the affected products. The company has stopped short of explaining exactly what the precaution is. It has not clarified whether the withdrawal relates to contamination, sterility concerns, manufacturing deficiencies, packaging issues or some other quality-related problem. Reports in sections of the media have suggested that the move may be linked to contamination concerns, but the company itself has neither confirmed nor elaborated on these reports, and that framing should be read as external speculation rather than a company admission.
This distinction matters. A manufacturer's voluntary withdrawal is legally and procedurally different from a regulator-directed recall following a confirmed quality failure. Whether the present action has been formally communicated to the Central Drugs Standard Control Organisation, and under what regulatory mechanism it is being handled, has not yet been clarified publicly. At the time of writing, neither the Central Drugs Standard Control Organisation nor Sun Pharma had issued a public advisory identifying affected batch numbers or setting out guidance for patients already using the products.
For patients, this lack of clarity is unsettling. Unlike tablets or capsules, ophthalmic products come into direct contact with delicate eye tissue and therefore must maintain sterility throughout manufacturing, packaging and use. Any compromise in sterility can potentially lead to serious eye infections, inflammation and, in severe cases, permanent damage to vision.
The withdrawal also raises an immediate practical concern for those who have already purchased these products. Many patients are likely to have been using these eye drops for days or even weeks before the withdrawal was announced. Because the action has been described as precautionary and no confirmed adverse-event data has been made public, there is at present no verified basis to conclude that patients who have already used these batches have suffered harm, nor has Sun Pharma advised consumers to discontinue treatment. Patients should therefore not panic or stop using prescribed medicines on their own, particularly those used to control glaucoma, where interruption of treatment can itself be harmful. Anyone currently using one of the withdrawn products should contact their ophthalmologist or prescribing doctor as soon as possible to determine whether an alternative product is required, and should retain the product packaging and batch number in case a formal adverse-event process follows. They should also seek immediate medical attention if they experience unusual redness, pain, swelling, discharge, blurred vision or any sudden change in eyesight after using the product.
From a business perspective, the withdrawal is unlikely to significantly affect Sun Pharma's overall financial performance, given its extensive portfolio of products across multiple therapeutic areas. However, ophthalmology remains an important segment of the company's business, and temporary shortages may create opportunities for competing manufacturers, particularly in glaucoma and post-operative eye care where continuity of treatment is essential.
More importantly, the episode highlights a broader issue in India's pharmaceutical sector: the need for greater transparency when products are withdrawn from the market. Voluntary withdrawals are, in many ways, a sign that a company is willing to act before a potential problem escalates. But a withdrawal without an accompanying explanation, communicated initially through the distribution chain rather than through a detailed public advisory to patients and prescribers, leaves doctors, pharmacists and patients relying on speculation instead of facts.
Patients and prescribing doctors have a legitimate interest in knowing whether the withdrawal affects specific batches or all batches, whether any adverse events have been reported, whether products already in use are considered safe, and what exactly prompted the company's decision. Clear communication is not merely good corporate practice, it is an integral part of patient safety.
Sun Pharma may well have taken the correct decision in withdrawing the products as a precaution. If the withdrawal ultimately proves to be a routine quality-control measure, prompt disclosure will reinforce confidence in both the company and the regulatory system. If prolonged silence continues, however, the episode risks shifting the focus from the quality of the withdrawn products to the quality of communication surrounding them. In healthcare, transparency is not an optional public relations exercise. It is part of patient safety itself.
